FATE R&D to Revenue
Fate Therapeutics Inc · R&D to Revenue
FATE R&D to Revenue
Latest reported1171.33%period ending
FATE Quarterly R&D/Revenue (627.84% → 1171.33%)
Latest values, visible window
High-resolution chart · PNG
FATE r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 1,171.3256% | |
| 1,677.0593% | |
| 1,857.195% | |
| 1,484.0896% | |
| 1,438.3849% | |
| 1,788.582% | |
| 1,806.9355% | |
| 1,127.1958% | |
| 510.9864% | |
| 1,669.5065% | |
| 1,898.3294% | |
| 1,763.1173% | |
| 4,381.1361% | |
| 111.2733% | |
| 196.5709% | |
| 532.7882% | |
| 438.3363% | |
| 391.7617% | |
| 407.2588% | |
| 373.4974% | |
| 358.0599% | |
| 402.5489% | |
| 245.2315% | |
| 406.1127% | |
| 487.9963% | |
| 1,164.1352% | |
| 899.6788% | |
| 955.2079% | |
| 767.8736% | |
| 673.5562% | |
| 848.5852% | |
| 1,329.1423% | |
| 1,637.3905% | |
| 1,118.5185% | |
| 962.7069% | |
| 836.0624% | |
| 772.6121% | |
| 775.6573% | |
| 606.6212% | |
| 663.1579% | |
| 660.37% | |
| 501.9667% | |
| 504.9257% | |
| 487.6218% | |
| 1,476.2918% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| -312.1524% | |
| 1,616.2679% | |
| 1,057.5862% | |
| 536.2288% | |
| 529.2379% | |
| 627.8409% |